Updated data from the Iressa® survival in lung cancer trial

Clinical Lung Cancer

Volumn 6, Issue 6, 2005, Pages 340-342

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PLACEBO; VASCULOTROPIN;

ADULT; ANOREXIA; ARTICLE; ASIAN; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; ETHNOLOGY; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PROTEIN EXPRESSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SMOKING; VOMITING;

EID: 26444556501     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-7304(11)70364-3     Document Type: Article

References (16)

1. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3:515-522.
2. Ohsaki Y, Tanno S, Fujita Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000; 7:603-607.
3. Kanematsu T, Yano S, Uehara H, et al. Phosphory-lation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res 2003: 13:289-298.
4. Mukohara T, Kudoh S, Yamauchi S, et al. Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer 2003; 41:123-130.
5. Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpresaion correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004; 15:28-32.
6. Lai WW, Chen FF, Wu MH, et al. Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer. Ann Thorac Surg 2001; 72:1868-1876.
7. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.
8. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-2158.
9. Fukuoka M, Yano S, Giaccone C, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
10. Giaccone C, Herbst RS, Manegold C. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer a phase III trial-INTACT 1. J Clin Oncol 2004; 22:777-784.
11. Herbst RS, Giaccone G, Schiller JH. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22:785-794.
12. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22:14s (Abstract #7010).
13. Herbst RS, Prager D, Hermann R, et al. TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22:14s (Abstract #7011).
14. Shepherd F, Peteira J, Ciuleanu T, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol 2004; 22:14s (Abstract #7022).
15. Iressa® (ZD1839, gefitinib) Tablets, Oncologic Drugs Advisory Committee (ODAC) Meeting Briefing Document, Match 4, 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/ 2005-4095B2_01_01-AstraZeneca-Iressa.pdf Accessed May 5, 2005.
16. Thatcher N, Chang A, Parikh P. et al. Results from a phase III placebo-controlled study (ISEL) of gefitinib (Iressa) plus best supportive care in patients with advanced non-small-cell lung cancer (NSCLC) who had received 1 or 2 prior chemotherapy regimens. Presented at: 96th Annual Meeting of the American Association of Cancer Research; April 16-20, 2005; Anaheim, CA. Abstract #LB-6.